Drug Information

Drug General Information
Drug ID
D05PKT
Former ID
DNC011112
Drug Name
4-[4-(6-methoxynaphthalen-2-yl)benzyl]pyridine
Drug Type
Small molecular drug
Indication Discovery agent Investigative [531085]
Formula
C23H19NO
Canonical SMILES
COC1=CC2=C(C=C1)C=C(C=C2)C3=CC=C(C=C3)CC4=CC=NC=C4
InChI
1S/C23H19NO/c1-25-23-9-8-21-15-20(6-7-22(21)16-23)19-4-2-17(3-5-19)14-18-10-12-24-13-11-18/h2-13,15-16H,14H2,1H3
InChIKey
XDUUJWUQYXFHEK-UHFFFAOYSA-N
PubChem Compound ID
46901928
Target and Pathway
Target(s) 17 alpha-hydroxylase-C17, 20-lyase Target Info Inhibitor [531085]
BioCyc Pathway Superpathway of steroid hormone biosynthesis
Glucocorticoid biosynthesis
Androgen biosynthesis
KEGG Pathway Steroid hormone biosynthesis
Metabolic pathways
Ovarian steroidogenesis
Prolactin signaling pathway
PathWhiz Pathway Androgen and Estrogen Metabolism
Steroidogenesis
Reactome Androgen biosynthesis
Glucocorticoid biosynthesis
Endogenous sterols
WikiPathways Metapathway biotransformation
Steroid Biosynthesis
Oxidation by Cytochrome P450
Metabolism of steroid hormones and vitamin D
Glucocorticoid & Mineralcorticoid Metabolism
Prostate Cancer
Phase 1 - Functionalization of compounds
References
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.